Technical Analysis for LIXT - Lixte Biotechnology Holdings, Inc.

Grade Last Price % Change Price Change
D 2.45 6.06% 0.14
LIXT closed up 6.06 percent on Monday, March 18, 2024, on 6 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Mar 27
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Gapped Up Strength 0.00%
20 DMA Resistance Bearish 6.06%
Crossed Above 50 DMA Bullish 6.06%
Fell Below 50 DMA Bearish 7.93%
20 DMA Resistance Bearish 2.94%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.94%
Inside Day Range Contraction 2.94%

   Recent Intraday Alerts

Alert Time
Possible Inside Day about 10 hours ago
Possible NR7 about 11 hours ago
Gap Up Closed about 11 hours ago
Rose Above 20 DMA about 12 hours ago
10 DMA Support about 12 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Lixte Biotechnology Holdings, Inc. Description

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Development Treatment Of Cancer Drug Discovery Biomarkers Neurodegenerative Diseases X Ray Metabolic Disease Sarcoma Degenerative Disease Immune Checkpoint Cancer Center National Cancer Institute Biomarker Technology Vascular And Metabolic Diseases

Is LIXT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.4999
52 Week Low 0.472
Average Volume 46,166
200-Day Moving Average 2.93
50-Day Moving Average 2.28
20-Day Moving Average 2.44
10-Day Moving Average 2.41
Average True Range 0.24
RSI (14) 51.92
ADX 14.62
+DI 18.42
-DI 21.48
Chandelier Exit (Long, 3 ATRs) 2.11
Chandelier Exit (Short, 3 ATRs) 2.61
Upper Bollinger Bands 2.72
Lower Bollinger Band 2.16
Percent B (%b) 0.52
BandWidth 23.04
MACD Line 0.01
MACD Signal Line 0.04
MACD Histogram -0.025
Fundamentals Value
Market Cap 5.51 Million
Num Shares 2.25 Million
EPS -3.24
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 0.00
Price-to-Book 3.26
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.68
Resistance 3 (R3) 2.65 2.55 2.64
Resistance 2 (R2) 2.55 2.49 2.56 2.62
Resistance 1 (R1) 2.50 2.46 2.53 2.53 2.61
Pivot Point 2.40 2.40 2.41 2.41 2.40
Support 1 (S1) 2.35 2.34 2.38 2.38 2.29
Support 2 (S2) 2.25 2.31 2.26 2.28
Support 3 (S3) 2.20 2.25 2.26
Support 4 (S4) 2.23